Pelago Bioscience AB and OmicScouts GmbH launched a commercial and scientific collaboration involving the use of the Cellular Thermal Shift Assay (CETSA™) for determination and quantification of drug-target interactions, according to BioSpace.com. Under the agreement, Pelago Bioscience grants OAlready a subscriber Login You have read all your free articles, to…